187 results on '"Blaustein, Robert O."'
Search Results
2. Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Clinical outcome results from the CHART-HF study
3. Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial
4. Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat
5. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA
6. Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy
7. Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF
8. Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat
9. Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study
10. Treatment patterns of patients with worsening heart failure with reduced ejection fraction.
11. Abstract 11603: Comparing Analytical Methods for Composite Endpoints in Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial
12. Abstract 11574: Relationship Between Baseline Electrocardiographic Parameters and Outcomes in Patients With High-Risk Heart Failure With Reduced Ejection Fraction: Insights From the Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial
13. Abstract 11453: Age, Sex, and Outcomes in Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial
14. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science
15. Bayesian Meta-analysis of Safety Outcomes Using Blinded Clinical Trial Data
16. Accelerometer vs. other activity measures in heart failure with preserved ejection fraction: the VITALITY‐HFpEF trial.
17. Nonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat
18. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia
19. Relationship between baseline electrocardiographic measurements and outcomes in patients with high‐risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial.
20. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia
21. Impact of ADCY9 Genotype on Response to Anacetrapib
22. Rationale and Design of the VITALITY-HFpEF Trial
23. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum
24. Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis
25. HDL-cholesterol levels and risk of age-related macular degeneration: a multiethnic genetic study using Mendelian randomization
26. Structural insights into neuronal K⁺ channel-calmodulin complexes
27. Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties
28. Anthrax Toxin: Channel-Forming Activity of Protective Antigen in Planar Phospholipid Bilayers
29. Defining changes in physical limitation from the patient perspective: insights from the VITALITY‐HFpEF randomized trial.
30. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction.
31. Preventing voltage-dependent gating of anthrax toxin channels using engineered disulfides
32. Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP
33. Constraints on voltage sensor movement in the Shaker [K.sup.+] channel
34. Sizing the protein translocation pathway of colicin Ia channels
35. Kinetics of tethering quaternary ammonium compounds to [K.sup.+] channels
36. Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case
37. Ion channels: Shake, rattle or roll?
38. Topography of Diphtheria Toxin's T Domain in the Open Channel State
39. Characterization of Anacetrapib Distribution into the Lipid Droplet of Adipose Tissue in Mice and Human Cultured Adipocytes
40. Differences in short and long-term survival between males and females with new-onset heart failure: A retrospective cohort study
41. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
42. Comprehensive healthcare resource use among newly diagnosed congestive heart failure
43. HDL-cholesterol levels and risk of age-related macular degeneration: a multiethnic genetic study using Mendelian randomization.
44. Impact of ADCY9Genotype on Response to Anacetrapib
45. Characterization of Anacetrapib Distribution into the Lipid Droplet of Adipose Tissue in Mice and Human Cultured Adipocytes
46. A Randomized, Open-Label, Dose-Response Study of Losartan in Hypertensive Children
47. Structural insights into neuronal K + channel–calmodulin complexes
48. Structural Insights into Calmodulation of Neuronal KCNQ Channels
49. The anthrax toxin channel: a barrel of LFs
50. Pinpointing Calmodulin on Functioning KCNQ Channels
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.